Arexvy has also been expanded to adults 59 years of age and younger for the prevention of respiratory syncytial virus lower respiratory tract disease.
FDA approves GSK’s Alexi for prevention of respiratory syncytial virus infection in adults aged 50-59 years at high risk
Leave a comment
